特立帕肽可增加全膝关节置换术后的假体周围骨密度:一项前瞻性研究
纳入22膝(17例患者)的前瞻性研究,比较特立帕肽组与对照组全膝关节置换术后假体周围骨密度变化。调整基线骨密度差异后,特立帕肽组6个月时R3(后髁)和R4(外侧)显著升高,12个月时R2(前髁)、R3(后髁)和R6(胫骨骨干)显著升高;6和12个月时特立帕肽组所有区域调整后平均骨密度均高于对照组。作者认为特立帕肽可能是骨质疏松患者TKA术后保留或改善假体周围骨密度的合理治疗选择。
要点
- 调整基线骨密度差异后,特立帕肽组6个月时R3(后髁)和R4(外侧)骨密度显著升高。
- 12个月时特立帕肽组R2(前髁)、R3(后髁)和R6(胫骨骨干)骨密度显著升高。
- 6和12个月时特立帕肽组所有区域调整后平均骨密度均高于对照组。
核心结论
- 作者认为特立帕肽可能是骨质疏松患者TKA术后保留或改善假体周围骨密度的合理治疗选择。
研究设计与样本
- 前瞻性研究,纳入22膝(17例患者),并根据病历识别接受TKA的对照组患者。
- 采用双能X线吸收法测量膝关节、髋部和腰椎不同部位,在基线、6个月和12个月测量感兴趣区以估算骨密度。
主要发现
- 调整两组基线骨密度差异后,特立帕肽组6个月时R3(后髁)和R4(外侧)骨密度显著升高。
- 调整两组基线骨密度差异后,特立帕肽组12个月时R2(前髁)、R3(后髁)和R6(胫骨骨干)骨密度显著升高。
- 6和12个月时特立帕肽组所有区域调整后平均骨密度均高于对照组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Teriparatide is a currently available therapeutic agent for osteoporosis. Previous studies have reported that teriparatide affects periprosthetic bone mineral density (BMD) after total knee arthroplasty (TKA). However, little agreement has been reached concerning the treatment of periprosthetic BMD after TKA with teriparatide. Moreover, BMD in the femoral and tibial sides of the joints together has never been examined. We investigated the efficacy of teriparatide to inhibit BMD loss in the femoral and tibial side and considered complications such as migration and periprosthetic fractures after TKA. METHODS: Twenty-two knees in 17 patients were included in this study, and a control group of patients who underwent TKA was identified according to their medical records. Dual-energy X-ray absorptiometry was performed for different locations (knee, hip, and lumbar spine), and regions of interest were measured to estimate BMD at initiation of the study as a baseline reference, followed by subsequent measurements at 6 and 12 months. RESULTS: As a result of adjusting the difference between the BMDs of the 2 groups at initiation, there was a significant increase in R3 (posterior condyle) and R4 (lateral) at 6 months. Furthermore, there was a significant increase in R2 (anterior condyle), R3 (posterior condyle), and R6 (tibial diaphysis) at 12 months. The study group had a higher adjusted mean BMD in all regions than did the control group at 6 and 12 months. CONCLUSION: Teriparatide may be a reasonable treatment option for osteoporotic patients to preserve or improve periprosthetic BMD after TKA.
引用
- Suzuki T, Sukezaki F, Shibuki T, et al. Teriparatide Administration Increases Periprosthetic Bone Mineral Density After Total Knee Arthroplasty: A Prospective Study. J Arthroplasty. 2017. PMID: 28869116. doi:10.1016/j.arth.2017.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。